Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study.

The participating registries agree with the Declaration of Helsinki and received approval from local ethics committees. The results of the study will be published in scientific journals and presented at international dermatology conferences by the end of 2023.